Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

A recent study from the Federal University of São Paulo (UNIFESP) has found that using infrared light along with regular ...

The National Comprehensive Cancer Network® (NCCN®)?an alliance of leading cancer centers?today announced the publication of a ...

Researchers have developed a non-addictive painkiller that remains inactive until it reaches sites of chronic pain. Instead of dulling the nerves that send the pain signals like other analgesics, this ...

Rather than merely masking pain signals like conventional analgesics, this new medication directly tackles the root cause of ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...

If you’re suffering from stabbing pain, numbness, tingling or a burning sensation in your arms, legs, hands or feet, you may ...

Detailed price information for Artelo Biosciences Inc (ARTL-Q) from The Globe and Mail including charting and trades.

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after ...